Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.

Autor: Brivio E; Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Baruchel A; Hématologie-Immunologie Pédiatrique, Hoˆ pital Universitaire Robert Debré (APHP) and Université de Paris, Paris, France., Beishuizen A; Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Bourquin JP; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland., Brown PA; Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Cooper T; Aflac Cancer and Blood Disorders Center/Children's Healthcare of Atlanta/Emory University, Atlanta, GA, USA., Gore L; University of Colorado School of Medicine and Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, USA., Kolb EA; Nemours Center for Cancer and Blood Disorders, Nemours/Alfred I DuPont Hospital for Children, Wilmington, DE, USA., Locatelli F; Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome, Italy., Maude SL; Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Mussai FJ; Institute for Immunology and Immunotherapy, Cancer Research UK Birmingham Centre, The University of Birmingham, Birmingham, United Kingdom., Vormoor-Bürger B; Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands., Vormoor J; Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands; University Medical Center, Utrecht, the Netherlands; Newcastle University, Newcastle, UK., von Stackelberg A; Charité-Children's Hospital Berlin, Berlin, UK., Zwaan CM; Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands; The Innovative Therapies for Children with Cancer Consortium, Paris, France. Electronic address: c.m.zwaan@prinsesmaximacentrum.nl.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Mar; Vol. 164, pp. 1-17. Date of Electronic Publication: 2022 Feb 01.

The development of targeted new agents to improve the outcome for children with leukemia.

Autor: Bautista F; a Department of Pediatric Oncology, Hematology and Stem Cell Transplantation , Hospital Niño Jesús , Madrid , Spain., Van der Lugt J; b Department of Pediatric Oncology/Hematology , Erasmus-MC Sophia Children's Hospital , Rotterdam , The Netherlands., Kearns PR; c Cancer Research UK Clinical Trials Unit, School of Cancer Sciences , University of Birmingham , Birmingham , UK., Mussai FJ; c Cancer Research UK Clinical Trials Unit, School of Cancer Sciences , University of Birmingham , Birmingham , UK., Zwaan CM; b Department of Pediatric Oncology/Hematology , Erasmus-MC Sophia Children's Hospital , Rotterdam , The Netherlands., Moreno L; a Department of Pediatric Oncology, Hematology and Stem Cell Transplantation , Hospital Niño Jesús , Madrid , Spain.

Publikováno v: Expert opinion on drug discovery [Expert Opin Drug Discov] 2016 Nov; Vol. 11 (11), pp. 1111-1122. Date of Electronic Publication: 2016 Sep 27.

Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.

Autor: Mussai FJ; Pediatric Oncology Branch, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY

Publikováno v: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2008 Aug; Vol. 30 (8), pp. 612-7.